After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Immunovant Inc is $4.15B. A total of 1.09 million shares were traded on the day, compared to an average of 1.76M shares.
In the most recent transaction, Geffner Michael sold 2,595 shares of IMVT for 19.03 per share on Oct 22 ’25. After the transaction, the Chief Medical Officer now owns 217,958 company shares. In a previous transaction on Oct 22 ’25, Stout Jay S sold 2,520 shares at 19.03 per share. IMVT shares that Chief Technology Officer owns now total 200,814.
Among the insiders who sold shares, Geffner Michael disposed of 1,272 shares on Oct 08 ’25 at a per-share price of $16.30. This resulted in the Chief Medical Officer holding 220,553 shares of IMVT after the transaction. In another insider transaction, Stout Jay S sold 1,585 shares at $16.30 per share on Oct 08 ’25. Company shares held by the Chief Technology Officer now total 203,334.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, IMVT has a high of $29.49 and a low of $12.72.
As of this writing, IMVT has an earnings estimate of -$0.7 per share for the current quarter. EPS was calculated based on a consensus of 10.0 estimates, with a high estimate of -$0.57 per share and a lower estimate of -$0.76. The company reported an EPS of -$0.76 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. IMVT’s latest balance sheet shows that the firm has $493.82M in Cash & Short Term Investments as of fiscal 2022. There were $2.36M in debt and $44.52M in liabilities at the time. Its Book Value Per Share was $2.98, while its Total Shareholder’s Equity was $469.82M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IMVT is Buy with a score of 4.44.
